Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: The first intervention group: Diphereline 11.25 mg, manufactured by Ipsen France, will be given to patients every three months for one year. Intervention 2: The second intervention gro
Sponsors
Homa Pharmed Company
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Positive estrogen and progesterone receptor Premenopausal patients Perimenopausal patients, if they have the same estradiol levels as premenopausal women.
Exclusion criteria
Exclusion criteria: Existence of metastasis History of hysterectomy and oophorectomy
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Menopausal symptoms. Timepoint: Before the intervention, three, six, nine and twelve months after the intervention. Method of measurement: Menopause Rating Scale.;Drug side effects. Timepoint: Before the intervention, three, six, nine and twelve months after the intervention. Method of measurement: Drug side effects checklist. | — |
Primary
| Measure | Time frame |
|---|---|
| Changes in Estradiol level over one year. Timepoint: Before the intervention, 3, 6 and 12 months after the intervention. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSafa Najjar Najafi
Iranian academic center for education culture and research
Outcome results
None listed